Sandoz launches Hyrimoz® (biosimilar adalimumab) in Canada

Feb 17, 2021

Sandoz announced that it has launched Hyrimoz®, its 50mg/mL biosimilar adalimumab in Canada. Hyrimoz® was approved by Health Canada in November 2020 with a full label. It was also previously launched in Europe in 2018.

Print Page Mail Article